There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.
PD1 x VEGF bispecific landscape: examining Hope versus Hype.
Previous
Previous
Novel Bispecific therapies in oncology
Next
Next